ArticlePloS one2012
JunD/AP-1-mediated gene expression promotes lymphocyte growth dependent on interleukin-7 signal transduction.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- The transcription factor BATF pioneers the differentiation program of effector CD8Cell reports · 2025Article
- Granzyme mRNA-miRNA interaction and its implication to functional impact.Genes & genomics · 2024Article
- NRF2 is a spatiotemporal metabolic hub essential for the polyfunctionality of Th2 cells.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Single-cell RNA sequencing reveals myeloid and T cell co-stimulation mediated by IL-7 anti-cancer immunotherapy.British journal of cancer · 2024Article
- A computational modeling of pri-miRNA expression.PloS one · 2024Article
- Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models.The Journal of clinical investigation · 2023Article
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.Journal for immunotherapy of cancer · 2023Article
- A systematic evaluation of the computational tools for ligand-receptor-based cell-cell interaction inference.Briefings in functional genomics · 2022Article
- A deep learning method for miRNA/isomiR target detection.Scientific reports · 2022Article
- Inhibition of NFAM1 suppresses phospho-SAPK/JNK signaling during osteoclast differentiation and bone resorption.Journal of cellular biochemistry · 2021Article
- The molecular and epigenetic mechanisms of innate lymphoid cell (ILC) memory and its relevance for asthma.The Journal of experimental medicine · 2021Article
- STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.Blood advances · 2018Article
- Consecutive epigenetically-active agent combinations act inOncotarget · 2018Article
- Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription.The Journal of experimental medicine · 2017Article
- Efflux Transporters Regulate Arsenite-Induced Genotoxicity in Double Negative and Double Positive T Cells.Toxicological sciences : an official journal of the Society of Toxicology · 2017Article
- T Cell Receptor and Cytokine Signaling Can Function at Different Stages to Establish and Maintain Transcriptional Memory and Enable T Helper Cell Differentiation.Frontiers in immunology · 2017Review
- Hexokinase is a key regulator of energy metabolism and ROS activity in insect lifespan extension.Aging · 2016Article
- Interleukin-7 receptor controls development and maturation of late stages of thymocyte subpopulations.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin-7 (IL-7) is an essential cytokine for lymphocyte growth that has the potential for promoting immune reconstitution. This feature makes IL-7 an ideal candidate for therapeutic development. As with other cytokines, signaling through the IL-7 receptor induces the JAK/STAT pathway. However, the broad scope of IL-7 regulatory targets likely necessitates the use of other signaling components whose identities remain poorly defined. To this end, we used an IL-7 dependent T-cell line to examine how expression of the glycolytic enzyme, Hexokinase II (HXKII) was regulated by IL-7 in a STAT5-independent manner. Our studies revealed that IL-7 promoted the activity of JNK (Jun N-terminal Kinase), and that JNK, in turn, drove the expression of JunD, a component of the Activating Protein 1 (AP-1) transcription factors. Gel shifts showed that the AP-1 complex induced by IL-7 contained JunD but not c-Fos or c-Jun. Inhibition of JNK/JunD blocked glucose uptake and HXKII gene expression, indicating that this pathway was responsible for promoting HXKII expression. Because others had shown that JunD was a negative regulator of cell growth, we performed a bioinformatics analysis to uncover possible JunD-regulated gene targets. Our search revealed that JunD could control the expression of proteins involved in signal transduction, cell survival and metabolism. One of these growth promoters was the oncogene, Pim-1. Pim-1 is an IL-7-induced protein that was inhibited when the activities of JNK or JunD were blocked, showing that in IL-7 dependent T-cells JunD can promote positive signals transduced through Pim-1. This was confirmed when the IL-7-induced proliferation of CD8 T-cells was impaired upon JunD inhibition. These results show that engagement of the IL-7 receptor drives a signal that is more complex than the JAK/STAT pathway, activating JNK and JunD to induce rapid growth stimulation through the expression of metabolic and signaling factors like HXKII and Pim-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.